| For: | Nassri AB, Muenyi V, AlKhasawneh A, Ribeiro BDS, Scolapio JS, Malespin M, de Melo Jr SW. Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report. World J Gastrointest Pharmacol Ther 2019; 10(1): 29-34 [PMID: 30697447 DOI: 10.4292/wjgpt.v10.i1.29] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v10/i1/29.htm |
| Number | Citing Articles |
| 1 |
Alan Su, Rodrigo Pedraza, Hagen Kennecke. Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer. Current Oncology 2023; 30(4) doi: 10.3390/curroncol30040279
|
| 2 |
David Anson, Joseph Norton, Benjamin Chaucer, Saurabh Bansal. Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation. Case Reports in Oncological Medicine 2019; 2019 doi: 10.1155/2019/7896749
|
| 3 |
Preeya Goyal, Justin T. Moyers, Bassem G. Elgohary, Muhammad B. Hammami. Case Report: Nivolumab-Induced Autoimmune Pancreatitis. Journal of Immunotherapy and Precision Oncology 2021; 4(4) doi: 10.36401/JIPO-21-11
|
| 4 |
Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Fernando Rivera, María-Carlota Londoño. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU. Gastroenterología y Hepatología (English Edition) 2024; 47(4) doi: 10.1016/j.gastre.2023.10.003
|
| 5 |
Malvika Gupta, Christopher Graham, Supriya Gupta. Immune Checkpoint Inhibitor-Associated Celiac Disease: A Retrospective Analysis and Literature Review. Diseases 2024; 12(12) doi: 10.3390/diseases12120315
|
| 6 |
Neeta Malviya, Ian W. Tattersall, Jonathan Leventhal, Allireza Alloo. Cutaneous immune-related adverse events to checkpoint inhibitors. Clinics in Dermatology 2020; 38(6) doi: 10.1016/j.clindermatol.2020.06.011
|
| 7 |
Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Fernando Rivera, María-Carlota Londoño. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU. Gastroenterología y Hepatología 2024; 47(4) doi: 10.1016/j.gastrohep.2023.10.009
|
| 8 |
Carolina Lopes, Sandra Morgado, Ana I. Plácido, Fátima Roque, Manuel Morgado. Critical Analysis of Immune Checkpoint Inhibitor Immunotoxicity Management. SN Comprehensive Clinical Medicine 2021; 3(1) doi: 10.1007/s42399-020-00670-w
|
| 9 |
Mar Riveiro-Barciela, Sabela carballal, Álvaro Díaz-González, Miriam Mañosa, Javier Gallgo-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Fernando Rivera, María-Carlota Londoño. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU. Revista Española de Enfermedades Digestivas 2024; doi: 10.17235/reed.2024.10250/2024
|
| 10 |
Manuel Morgado, Ana Plácido, Sandra Morgado, Fátima Roque. Management of the Adverse Effects of Immune Checkpoint Inhibitors. Vaccines 2020; 8(4) doi: 10.3390/vaccines8040575
|
| 11 |
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Läubli. Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for ImmunoTherapy of Cancer 2024; 12(1) doi: 10.1136/jitc-2023-007409
|
| 12 |
Dua Abuquteish, Ahmad Yousef Alazzam, Aws Khalid Abushanab, Omar Amjad Almajdoubah, Sara Aljfout, Mahmoud Taysir Mousa, Mus’ab Theeb Mustafa, Bashar Khater, Maher Sughayer. Iatrogenic effect of immune checkpoint inhibitors and targeted therapies on the lower gastrointestinal tract. Frontline Gastroenterology 2025; doi: 10.1136/flgastro-2025-103094
|